CVS Health Corp. stock faces $2 billion Medicare rating dispute

Published on 10/29/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health Corp. stock is in focus after Aetna challenged the methodology behind its 2027 Medicare Advantage ratings. The case adds regulatory uncertainty.

Medicare-Ratings werden zum Rechtsrisiko

Die Klage richtet sich gegen 28 Qualitätsmaßnahmen, die CMS zur Berechnung der Ratings 2027 verwendet haben soll.
Der Anteil der Aetna-Mitglieder in Plänen mit mindestens vier Sternen sank laut Klage von 84 Prozent auf 67 Prozent.
Ein Gericht hat über die Vorwürfe bislang nicht in der Sache entschieden.

CVS Health Corp., US1266501006, Illustration mit AI erstellt.

CVS Health Corp. stock is in focus after CVS Health, Aetna and affiliated insurers filed a federal lawsuit on October 26, 2026, challenging the methodology used for the companies' 2027 Medicare Advantage star ratings. Healthcare Dive reported that CVS is asking a Georgia federal court to vacate the ratings and require a recalculation.

What has changed since the last report

The complaint challenges 28 measures used by the Centers for Medicare and Medicaid Services. CVS says those measures were adopted without the required notice-and-comment process and that the agency also relied on data sources outside its legal authority. The allegations remain untested, and no ruling on the merits has been issued.

The dispute matters because star ratings influence Medicare Advantage bonus payments, rebates and the attractiveness of plans to members. Healthcare Dive reported that the share of CVS members enrolled in Aetna Medicare plans rated at least four stars fell from 84 percent in 2026 to 67 percent in 2027. CVS says the lower ratings could reduce payments tied to 2028. The company is seeking a higher rating for 43 contracts.

Share price and investor context

At Lang & Schwarz, the stock traded at 80.93 EUR on October 29, 2026, at 16:08 Berlin time. That was 0.50 percent below the previous Xetra session's close of 81.34 EUR on October 28, based on the Xetra quote shown by Yahoo Finance. The current legal challenge adds a potentially material policy and execution issue, but its financial outcome depends on the court process and any subsequent CMS action.

For investors, the immediate question is whether CVS can secure a recalculation before the ratings affect future payment and plan-positioning decisions. The lawsuit does not by itself restore any rating or guarantee additional revenue.

A real-time quote of CVS Health Corp. stock is available separately.